Ultra-low dose ketamine and memantine treatment for pain in an opioid-tolerant oncology patient.

Abstract

Patients taking high-dose opioids chronically for tumor-related or neuropathic pain may develop pain that is refractory to opioids. One option for control of such pain is the use of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine. We describe a case of opioid-refractory pain that responded to a low-dose IV infusion of ketamine in the inpatient setting. The patient was then successfully transitioned to oral memantine for long-term outpatient management, in a novel use of this oral NMDA receptor antagonist. We present recent findings from basic research on pain mechanisms to explain why opioid tolerance, as in this patient, may contribute to the analgesic benefit of NMDA receptor antagonists.

• Authors: Lucinda A Grande, Brendan R O'Donnell, Dermot R Fitzgibbon, Gregory W Terman
• Journal: Anesthesia and analgesia (Anesth Analg) Vol. 107 Issue 4 Pg. 1380-3 (Oct 2008) ISSN: 1526-7598 [Electronic] United States
• PMID: 18806055 (Publication Type: Case Reports, Journal Article)

Chemical References

• Analgesics
• Analgesics, Opioid
• Receptors, N-Methyl-D-Aspartate
• Ketamine
• Memantine

Topics

• Adult
• Analgesics (administration & dosage)
• Analgesics, Opioid (therapeutic use)
• Drug Tolerance
• Humans
• Ketamine (administration & dosage)
• Liposarcoma (complications, secondary)
• Male
• Memantine (administration & dosage)
• Pain Measurement
• Pain, Intractable (drug therapy, etiology)
• Receptors, N-Methyl-D-Aspartate (antagonists & inhibitors)
• Spinal Neoplasms (complications)